GSK plc reported strong first-quarter results for 2025, with total sales of £7.5 billion (up 2% AER, 4% CER) and a profit increase of 50%. They declared a dividend of 16p for Q1 and expect continued growth in sales, particularly in Specialty Medicines, which saw a 17% increase in sales to £2.9 billion, driven by strong performances in oncology and HIV treatments.